Analytical Validation of a Novel Point‐Of‐Care Quantitative Immunoassay for Feline N‐Terminal Pro‐Brain Natriuretic Peptide
Veterinary Clinical Pathology · 2025
DOI: 10.1111/vcp.70062 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Veterinary Clinical Pathology, 2025. Verfasst von Emily A Javery und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana-Champaign, Illinois, USA. Hauptthemen laut MEDLINE: Natriuretic Peptide, Brain, Peptide Fragments, Cat Diseases, Point-of-Care Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Point‐of‐care testing (POC) is widely utilized for rapid results for many different analytes. A new feline‐specific N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) quantitative assay (Vcheck V200, Bionote Inc) is currently available but has not undergone independent validation.
Objective
To validate the Vcheck POC quantitative assay for feline NT‐proBNP.
Methods
Validation was performed in accordance with the American Society for Veterinary Clinical Pathology guidelines utilizing serum samples from 62 cats. Precision was determined for low (50–100 pmol/L), mid (101–300 pmol/L), and high (> 301 pmol/L) pools short‐term (20 repetitions) and long‐term (5 repetitions each day for 5 days). Linearity, methods comparison, interference testing, and sample stability were evaluated.
Results
The within‐day coefficients of variability (CV) were low pool = 12.6%, mid pool = 10.4%, and high pool = 8.7%. The within‐week CV was low pool = 9.9%, mid pool = 14.9%, and high pool = 6.9%. The assay was linear over the analytical range of 53–1488 pmol/L ( R 2 = 0.99, p < 0.0001). Paired samples between the feline Cardiopet NT‐proBNP (IDEXX) and Vcheck assays demonstrated a mean difference of 11 pmol/L (2.3%), p = 0.38, between assays with minimal constant or proportional bias. Hemolysis and lipemia did not affect assay performance, while all icteric samples were invalid. Significantly lower values were identified in samples after 2 and 4 h when stored at 20°C and 4°C, respectively.
Conclusions
The Vcheck V200 has acceptable precision, accuracy, and compares favorably with commercially available assays and is a viable POC quantitative assay for feline NT‐proBNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana-Champaign, Illinois, USA.
ORCID-Profile: Ryan C Fries
Zitieren
APA
Javery, E. A., Fries, R. C., Kadotani, S., Kruckman, L., Humphries, L., Prabhakar, S. R., & Rosser, M. F. (2025). Analytical Validation of a Novel Point‐Of‐Care Quantitative Immunoassay for Feline N‐Terminal Pro‐Brain Natriuretic Peptide. Veterinary Clinical Pathology. https://doi.org/10.1111/vcp.70062
Vancouver
Javery EA, Fries RC, Kadotani S, Kruckman L, Humphries L, Prabhakar SR, et al. Analytical Validation of a Novel Point‐Of‐Care Quantitative Immunoassay for Feline N‐Terminal Pro‐Brain Natriuretic Peptide. Veterinary Clinical Pathology. 2025. doi:10.1111/vcp.70062
BibTeX
@article{Javery2025,
author = {Javery, Emily A and Fries, Ryan C and Kadotani, Saki and Kruckman, Leah and Humphries, Lindsey and Prabhakar, Sumana R and Rosser, Michael F},
title = {Analytical Validation of a Novel Point‐Of‐Care Quantitative Immunoassay for Feline N‐Terminal Pro‐Brain Natriuretic Peptide},
journal = {Veterinary Clinical Pathology},
year = {2025},
doi = {10.1111/vcp.70062}
}
EUVIMED